Zoledronic-d3 acid is a bisphosphonate compound, specifically a deuterated form of zoledronic acid, which is primarily used in the treatment of bone-related conditions such as osteoporosis and metastatic bone disease. The deuteration indicates that certain hydrogen atoms in the molecule are replaced with deuterium, a heavier isotope of hydrogen, which can enhance the stability and pharmacokinetic properties of the drug. Zoledronic-d3 acid functions by inhibiting osteoclast-mediated bone resorption, thereby reducing bone turnover and increasing bone mineral density. It is characterized by its high affinity for hydroxyapatite, the mineral component of bone, allowing it to effectively target and accumulate in bone tissue. The compound is typically administered intravenously and has a long half-life, contributing to its efficacy in maintaining bone health. As with other bisphosphonates, potential side effects may include gastrointestinal issues and, in rare cases, osteonecrosis of the jaw. Overall, zoledronic-d3 acid represents a valuable therapeutic option in managing various bone disorders.

Zoledronic-d3 Acid

1134798-26-7: Zoledronic-d3 acid is a bisphosphonate compound, specifically a deuterated form of zoledronic acid, which is primarily used in the treatment of bone-related conditions such as osteoporosis and metastatic bone disease. The deuteration indicates that certain hydrogen atoms in the molecule are replaced with deuterium, a heavier isotope of hydrogen, which can enhance the stability and pharmacokinetic properties of the drug. Zoledronic-d3 acid functions by inhibiting osteoclast-mediated bone resorption, thereby reducing bone turnover and increasing bone mineral density. It is characterized by its high affinity for hydroxyapatite, the mineral component of bone, allowing it to effectively target and accumulate in bone tissue. The compound is typically administered intravenously and has a long half-life, contributing to its efficacy in maintaining bone health. As with other bisphosphonates, potential side effects may include gastrointestinal issues and, in rare cases, osteonecrosis of the jaw. Overall, zoledronic-d3 acid represents a valuable therapeutic option in managing various bone disorders.

Stability Hygroscopic Applications Zoledronic-d3 Acid is the labeled analogue of Zoledronic Acid (Z623500), a biphosphonate bone resorption inhibitor. References Green, J.R., et al.: J. Bone Min. Res., 9, 745 (1994); Risser, F., et al.: J. Pharm. Biomed. Anal., 15, 1877 (1997); Body, J.J., Cancer, 80, 1699 (1997)

CAS 1134798-26-7

Zoledronic-d3 Acid

Zoledronic-d3 Acid

Ref: TR-Z623504